467. Antifungal Therapy in Candida Intra-abdominal Infections Following Source Control. (15th December 2022)

• Record Type: Journal Article
• Authors: Buck, Margaret; Carr, Dustin R; Bremmer, Derek N; Jenniches, Daniel; Babowice, James; Chung, Eunice L
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.525
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Current literature suggests that many surgical patients with Candida isolated from an intra-abdominal source do not develop symptomatic infections, however, Infectious Disease Society of America (IDSA) Guidelines recommend antifungal treatment in Candida intra-abdominal infections. An article published by Fabre et al found similar incidence of treatment failure between patients appropriately treated for Enterococcus intra-abdominal infections compared to patients without Enterococcus coverage following source control. Enterococcus and Candida are both low-virulent microorganisms, questioning the necessity of antifungal therapy following source control in Candida intra-abdominal infections. Methods: This was a retrospective, cohort study of adult patients with intra-abdominal infections who underwent source control and isolation of Candida in intra-abdominal cultures. Eligible patients were separated based on receipt of antifungals. Patients were excluded if they received between 24 hours and 3 days of antifungal therapy, had candidemia prior to intervention, or received prophylactic or therapeutic antifungals within 7 days of intervention. The antifungal group and non-antifungal group were assessed for incidence of treatment failure, defined as death or additional unplanned surgical or antimicrobial interventions for intra-abdominal infections. Results: A total of 125 patients were included with 77 patients (61.6%) receiving antifungal therapy and 48 patients (38.4%) not receiving antifungal therapy. Patients who received antifungal therapy had a higher median SAPS II score (29 vs 22.5; p = 0.003). There was no difference in the incidence of treatment failure at 30 days between the antifungal and non-antifungal groups (41.6% and 35.2%, respectively; p = 0.62). Median hospital length of stay (14 vs 8.5 days; p < 0.001) and median total duration of antimicrobial therapy (10 vs 7 days; p = 0.667) was longer in the antifungal group compared to the non-antifungal group, respectively. Conclusion: Patients with Candida intra-abdominal infections that underwent source control had a similar rate of treatment failure at 30 days regardless of receipt of antifungal therapy. However, those who received antifungal therapy had a higher severity of illness. Disclosures: Dustin R. Carr, PharmD, BCPS, BCIDP, Merck: Honoraria Derek N. Bremmer, PharmD, BCPS-AQ ID, Thermo Fisher Scientific: Honoraria.